NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
May 22 04:00PM ET
42.97
Dollar change
-0.22
Percentage change
-0.51
%
IndexRUT P/E- EPS (ttm)-2.73 Insider Own15.01% Shs Outstand42.00M Perf Week-1.22%
Market Cap1.81B Forward P/E23.57 EPS next Y1.82 Insider Trans-1.07% Shs Float35.71M Perf Month-14.06%
Income-104.94M PEG- EPS next Q-0.39 Inst Own101.08% Short Float23.27% Perf Quarter-10.18%
Sales233.67M P/S7.73 EPS this Y61.77% Inst Trans-11.02% Short Ratio11.29 Perf Half Y-3.72%
Book/sh8.15 P/B5.27 EPS next Y255.34% ROA-24.69% Short Interest8.31M Perf Year10.95%
Cash/sh9.71 P/C4.43 EPS next 5Y- ROE-33.98% 52W Range20.08 - 57.28 Perf YTD-22.39%
Dividend Est.- P/FCF- EPS past 5Y-66.60% ROI-25.32% 52W High-24.98% Beta0.86
Dividend TTM- Quick Ratio5.54 Sales past 5Y172.29% Gross Margin92.99% 52W Low113.97% ATR (14)2.24
Dividend Ex-Date- Current Ratio5.57 EPS Y/Y TTM42.86% Oper. Margin-46.72% RSI (14)38.96 Volatility2.77% 2.97%
Employees323 Debt/Eq0.21 Sales Y/Y TTM449.03% Profit Margin-44.91% Recom1.25 Target Price70.86
Option/ShortYes / Yes LT Debt/Eq0.21 EPS Q/Q36.93% Payout- Rel Volume0.48 Prev Close43.19
Sales Surprise8.15% EPS Surprise12.32% Sales Q/Q183.68% EarningsMay 01 AMC Avg Volume736.15K Price42.97
SMA20-7.16% SMA50-10.17% SMA200-1.74% Trades Volume350,700 Change-0.51%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Initiated Goldman Neutral $19
Jul-18-23Initiated William Blair Outperform $44
May-18-23Initiated Guggenheim Buy
Aug-01-22Initiated Barclays Overweight $40
Dec-21-21Initiated H.C. Wainwright Buy $40
Nov-23-21Initiated Oppenheimer Outperform $55
Nov-10-20Initiated Raymond James Strong Buy $39
Nov-10-20Initiated Ladenburg Thalmann Buy $42
Nov-10-20Initiated Jefferies Buy $35
Nov-10-20Initiated BofA Securities Buy $33
May-14-25 09:45AM
May-08-25 05:00PM
May-05-25 06:04PM
May-02-25 03:17AM
May-01-25 09:37PM
05:35PM Loading…
05:35PM
04:05PM
Apr-30-25 10:17AM
09:55AM
Apr-25-25 10:00AM
Apr-24-25 05:00PM
11:00AM
Apr-23-25 01:41PM
Apr-22-25 11:19AM
08:31AM
04:05PM Loading…
Apr-21-25 04:05PM
Mar-28-25 03:59PM
Mar-20-25 09:05AM
Mar-12-25 09:49PM
04:12PM
Mar-06-25 05:00PM
Feb-26-25 02:13AM
02:05AM
Feb-25-25 08:40AM
07:00AM
01:31AM
Feb-20-25 05:00PM
Jan-30-25 05:00PM
Jan-20-25 03:31PM
Jan-14-25 09:35AM
08:30AM Loading…
Jan-13-25 08:30AM
Dec-26-24 10:30AM
Dec-04-24 09:55AM
Nov-18-24 09:55AM
Nov-14-24 02:15AM
Nov-13-24 05:30PM
04:05PM
08:30AM
Nov-07-24 10:00AM
Nov-06-24 04:30PM
Nov-05-24 08:30AM
Oct-30-24 06:39AM
Oct-17-24 08:30AM
Oct-09-24 05:56PM
Sep-25-24 05:00PM
Aug-28-24 05:00PM
Aug-08-24 09:56PM
06:05PM
04:05PM
Jul-29-24 04:30PM
May-29-24 05:00PM
May-09-24 05:00PM
12:48PM
11:06AM
03:49AM
May-08-24 08:58PM
05:40PM
04:05PM
May-06-24 09:55AM
May-01-24 05:00PM
Apr-23-24 08:30AM
Apr-09-24 07:35AM
Apr-08-24 09:55AM
Apr-04-24 11:33AM
Apr-01-24 12:00PM
Mar-06-24 09:55AM
Mar-05-24 04:30PM
08:30AM
Mar-01-24 12:07AM
Feb-29-24 04:37PM
Feb-28-24 12:00PM
09:58AM
Feb-27-24 11:13PM
06:34AM
06:00AM
Feb-22-24 08:00AM
Feb-20-24 05:00PM
Jan-31-24 05:00PM
Jan-30-24 04:06AM
Jan-21-24 07:01AM
Dec-21-23 03:32PM
Dec-11-23 08:00AM
Dec-01-23 11:04PM
Nov-12-23 12:15PM
Nov-09-23 04:05PM
Nov-01-23 06:35PM
Sep-06-23 08:00AM
Aug-30-23 04:30PM
Aug-28-23 10:22AM
Aug-24-23 09:00AM
Aug-10-23 04:05PM
Aug-03-23 02:14PM
Aug-01-23 10:30PM
Jul-31-23 04:29PM
Jul-25-23 07:00AM
Jul-20-23 02:04PM
Jul-19-23 08:34PM
10:13AM
Jun-12-23 08:30AM
Jun-05-23 08:30AM
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Azamian Bobak R.President/CEO and Board ChairMar 24 '25Sale50.006,000300,000824,106Mar 26 04:47 PM
Azamian Bobak R.OfficerMar 24 '25Proposed Sale50.006,000300,000Mar 24 05:35 PM
Mottiwala AzizChief Commercial OfficerMar 18 '25Sale46.293,643168,63471,979Mar 20 09:49 PM
Mottiwala AzizChief Commercial OfficerMar 20 '25Sale50.113,365168,62065,057Mar 20 09:49 PM
Mottiwala AzizChief Commercial OfficerMar 19 '25Sale47.403,557168,60268,422Mar 20 09:49 PM
Neervannan SeshadriChief Operating OfficerMar 20 '25Sale50.112,435122,01879,682Mar 20 09:49 PM
Neervannan SeshadriChief Operating OfficerMar 18 '25Sale46.292,605120,58584,660Mar 20 09:49 PM
Neervannan SeshadriChief Operating OfficerMar 19 '25Sale47.402,543120,53882,117Mar 20 09:49 PM
Wahl BryanGeneral CounselMar 18 '25Sale46.293,341154,65558,057Mar 20 09:49 PM
Wahl BryanGeneral CounselMar 19 '25Sale47.403,261154,57154,796Mar 20 09:49 PM
Wahl BryanGeneral CounselMar 20 '25Sale50.113,084154,53951,712Mar 20 09:49 PM
Whitfield Dianne C.Chief Human Resources OfficerMar 18 '25Sale46.292,315107,16150,751Mar 20 09:48 PM
Whitfield Dianne C.Chief Human Resources OfficerMar 20 '25Sale50.112,137107,08546,355Mar 20 09:48 PM
Whitfield Dianne C.Chief Human Resources OfficerMar 19 '25Sale47.402,259107,07748,492Mar 20 09:48 PM
Azamian Bobak R.President/CEO and Board ChairMar 20 '25Sale50.118,534427,63953,635Mar 20 09:48 PM
Azamian Bobak R.President/CEO and Board ChairMar 19 '25Sale47.408,551405,31762,169Mar 20 09:48 PM
Azamian Bobak R.President/CEO and Board ChairMar 18 '25Sale46.297,131330,09470,720Mar 20 09:48 PM
Farrow Jeffrey SSee RemarksMar 19 '25Sale47.401,25459,44023,617Mar 20 09:48 PM
Farrow Jeffrey SSee RemarksMar 18 '25Sale46.291,28459,43624,871Mar 20 09:48 PM
Farrow Jeffrey SSee RemarksMar 20 '25Sale50.111,18659,43022,431Mar 20 09:48 PM
Whitfield Dianne C.OfficerMar 20 '25Proposed Sale50.112,137107,093Mar 20 04:35 PM
Farrow Jeffrey SOfficerMar 20 '25Proposed Sale50.111,18659,435Mar 20 04:30 PM
Mottiwala AzizOfficerMar 20 '25Proposed Sale50.113,365168,632Mar 20 04:29 PM
Wahl BryanOfficerMar 20 '25Proposed Sale50.113,084154,550Mar 20 04:21 PM
Neervannan SeshadriOfficerMar 20 '25Proposed Sale50.112,435122,026Mar 20 04:18 PM
Azamian Bobak R.OfficerMar 20 '25Proposed Sale50.118,534427,669Mar 20 04:11 PM
Neervannan SeshadriOfficerMar 19 '25Proposed Sale47.402,543120,536Mar 19 03:27 PM
Wahl BryanOfficerMar 19 '25Proposed Sale47.403,261154,569Mar 19 03:24 PM
Azamian Bobak R.OfficerMar 19 '25Proposed Sale47.408,551405,311Mar 19 03:23 PM
Whitfield Dianne C.OfficerMar 19 '25Proposed Sale47.402,259107,075Mar 19 03:22 PM
Farrow Jeffrey SOfficerMar 19 '25Proposed Sale47.401,25459,439Mar 19 03:12 PM
Mottiwala AzizOfficerMar 19 '25Proposed Sale47.403,557168,599Mar 19 03:12 PM
Neervannan SeshadriOfficerMar 18 '25Proposed Sale46.282,605120,571Mar 18 04:31 PM
Wahl BryanOfficerMar 18 '25Proposed Sale46.283,341154,637Mar 18 04:26 PM
Mottiwala AzizOfficerMar 18 '25Proposed Sale46.283,643168,614Mar 18 04:26 PM
Whitfield Dianne C.OfficerMar 18 '25Proposed Sale46.282,315107,149Mar 18 04:20 PM
Azamian Bobak R.OfficerMar 18 '25Proposed Sale46.287,131330,055Mar 18 04:15 PM
Farrow Jeffrey SOfficerMar 18 '25Proposed Sale46.281,28459,429Mar 18 04:12 PM
Goldberg Andrew D.DirectorMar 07 '25Option Exercise12.897,00090,23013,350Mar 11 04:01 PM
LINK WILLIAM J PHDDirectorAug 12 '24Sale26.0835,000912,9610Aug 14 04:34 PM
FLYING L PARTNERS XI LLCDirectorAug 12 '24Proposed Sale26.8535,000939,750Aug 12 04:25 PM
Farrow Jeffrey SSee RemarksJun 18 '24Sale27.4710,445286,92418,136Jun 20 04:26 PM